StemCell Therapy

AI company Lapetus Solutions has been developing analytical solutions for the insurance market that leverage biometric facial recognition with selfies to treat the face as a biomarker of human aging, writes Longevity Technology.

Professor at the University of North Carolina Wilmington, Karl Ricanek holds a PhD in computer science and has specifically focused on facial analytics. He founded Lapetus Solutions in 2015 together with Jay Olshansky, professor of gerontology at the University of Illinois at Chicago and founder of the field of biodemography.

Ricanek explained in an interview with Longevity Technology that just 10 years ago, insurance companies created life expectancy models based on blood analysis. In a meeting with life insurance companies, Ricanek heard Olshanskys presentation on people who are biologically aging slower and the indicators on the face that present themselves for long-lived individuals.

Its about understanding your origins, your genes, those things that are just innate in you, Ricanek told the publication. So, it was natural that we would look at the components of the face to understand biological age, or what were now calling in our product, our senescing rate. This is the rate at which youre aging, and it can be faster or slower, or normal. So, if you are senescing slower than normal, it basically means that you are likely to live longer than average. If youre senescing faster, then youre likely to live shorter.

Next year, Lapetus plans to release Janus, a facial analysis product that life insurance companies can integrate with their online application process. The company claims a medical selfie is all it takes for the system to accurately detect gender, age and BMI in less than two minutes. Another feature it is working on is susceptibility to chronic diseases.

After working in AI for some 30 years, Ricanek says that Only now are we getting to the point where the artificial intelligence, the hardware, and the ability to scale it up using cloud technology, has presented itself in such a way that we can solve these really challenging and, before now, just intractable problems.

Lapetus focus areas are longevity risk, life expectancy, medical underwriting and wealth management. Future plans include adding sensory analytics and saliva-based genetic testing, while researching other innovation related to aging measurement.

When you blend all of these things together, we can give you a more detailed picture of your life expectancy and your potential for chronic disease, says Ricanek. We havent done the blending part yet but thatll come next year.

With roughly eight or nine million secured, Lapetus has received support from a number of investors including SixThirtyandPlug and Play.

ageing | artificial intelligence | biometric data | biometrics | face photo | facial recognition | insurance | Lapetus Solutions

Read the original:
Lapetus Solutions working on biometrics-based selfie face analytics for aging - Biometric Update

Entrepreneur Dave Aspreys end-of-life plans are quite simple, really, even if some of his ambitions sound laughably optimistic to most of us.I want to die at a time and by a method of my own choosing, and keep doing awesome things until that day, he tells me. I dont think its outrageous to believe Ill make it to 180 years old. And if I run out of energy, itll just be because I did too much cool shit for my own good.

Asprey is strolling across his lush property in British Columbia, holding up his phone and pointing out the specimens in this years garden as we chat over Zoom in the midst of the global pandemic. Hes protecting his skin from the sun with a goofy Outdoor Research hat and wearing a long string of beads that he says are each over a hundred years old, from cultures around the world.

Asprey, 48, is the founder of the Bulletproof wellness empire and a vocal champion of the movement to extend human life expectancy beyond 100 years. Hes made millions by experimenting on his own body and packaging his home-brewed discoveries into books, a podcast, consulting services and consumer products (you may have even tried his butter-laced coffee). Asprey, who was a web-security executive before he became the Bulletproof Executive, is just one of a cadre of tech elite who have begun directing their attentionand truckloads of moneytoward the problem of life extension. Jeff Bezos, Peter Thiel, Sergey Brin, Larry Ellisonname a Silicon Valley A-lister and he or she is likely funding longevity research, experimenting with anti-aging interventions or both. These are the masters of the universe who see no reason they cant take the tech industrys optimization obsession and apply it to the ultimate challenge: conquering death itself.

And their efforts appear to be paying off: Thanks to a recent explosion of advances in longevity medicine, Aspreys vision of living healthfully into his second century might not be so crazy. In fact, for people in middle age right now, a handful of therapies in clinical trials have the potential, for the first time in human history, to radically transform what old age looks like. If the life extensionists are right, a person whos 40 today might reasonably expect to still be downhill skiing, running a 10K or playing singles tennis at 100.

Dave AspreyDave Asprey

If you do anti-aging right, Asprey insists, youll have a level of resilience and energy to fight what comes your way. If you get Covid-19, youre less likely to become very sick. The idea is that at a cellular level, youre making yourself very hard to kill.

The most extreme of the controversial interventions Asprey has undergone involved having stem cells extracted from his own bone marrow and fat and then injected into hundreds of locations on his body. Into every joint, between every vertebra and into my cerebrospinal fluid, face and sex organs, he tells me cheerfully. For what I spent on that, I could have bought a really nicely appointed Tesla.

He trots up a flight of stairs to his home office, which sits above a million-dollar lab filled with health gadgets, such as a cryochamber, a hypoxic trainer and an AI-enabled stationary bike. For a wealthy person, investing in your body should be a major part of your Im rich strategy, he explains. Personally, I think you should be spending at least 2 to 3 percent of your net worth on health and longevity. Get a personal chef who can cook you the right food. Its not that hard.

It might be an exaggeration to say BioViva CEO Liz Parrish believes death is optional, but for her, Aspreys goal of living to 180 shows a distinct lack of ambition. If you can reach homeostasis in the body, Parrish says, where its regenerating itself just a little bit faster than its degrading, then what do you die of? An accident or natural disaster, probably. Theres no expiration date at 90 or 100 years old.

Tall, blond and fit, Parrish cuts a strikingly youthful figure at 49one that might convince you to order whatever shes having. But, like Asprey, she has received criticism from the longevity research community for becoming patient zero in her own experimental drug trial, aimed at halting aging at the cellular level. In 2015, Parrish underwent telomerase and follistatin gene therapies in Bogota, Colombia. The procedures involved receiving around a hundred injections of a cocktail of genes and a virus modified to deliver those new genes into her bodys cells. The objective was to prevent age-related muscle loss and lengthen her telomeres: the caps at the end of our chromosomes. Scientists have identified their unraveling as not only a marker of aging but also a potential cause of age-related decline.

Liz ParrishLiz Parrish

Parrish told the media about her clandestine experiment and has published periodic updates on her condition in the five years since, and she reports that she has indeed increased her muscle mass and lengthened her telomeres. Parrishs punk-rock approach stems from her conviction that the medical-research communityboth the Food and Drug Administration (FDA) and researchers who arent business-mindedis moving too slowly, with too much red tape, when it comes to advancing aging therapeutics. But gene therapy is a relatively new area of medicine that brings with it a host of new risks, including cancer, severe immune reactions and infections caused by the viral vector used to deliver the drug.

Parrish downplays such worries. There may be risks, she tells Robb Report. But the known risk is that youre 100 percent likely to die. So you have to decide for yourself if the potential benefit outweighs that.

Humans have always aspired to find the fountain of youth, so people might be skeptical about the fact that anti-aging technologies are working now, says British investor and businessman Jim Mellon. But the fact is that this is finally happening, and we need to seize the moment. Mellon cofounded Juvenescence, a three-year-old pharmaceutical company thats investing in multiple technologies simultaneously to increase the odds of bringing winning products to market.

Mellon, 63, has made his fortune betting on well-timed investment opportunities, and he predicts that a new stock-market mania for life extension is just around the corner. This is like the internet dial-up phase of longevity biotech, he enthuses. If youd invested in the internet in the very early days, youd be one of the richest people on the planet. Were at that stage now, so the opportunity for investors is huge. According to a report by Bank of America Merrill Lynch, hes not wrong: The market for technologies to increase human life span is projected to grow sixfold to $610 billion in just the next five years.

When I talk to Mellon in the late spring, hes sequestered on the rugged coast of the Isle of Man, a tiny spit of land in the Irish Sea. Despite being what he describes as imprisoned there for 15 weeksand countingduring the Covid-19 shutdown, hes jovial and chatty and wants to make it clear that his interest in life extension is much more than financial. Working to extend life is an ethical cause, he says. If we can help people to live healthfully until the end of life, well transform the world completely. Well reduce a huge amount of pressure on failing health-care systems, and well have to reimagine pension and life insurance. This should be the number-one tick in anyones investment portfolio.

If youd like to get on board with this social-impact view of longevity, it helps to understand the trajectory of aging today. In Americas most affluent neighborhoods, the average life span is about 88 years. (Meanwhile, in this countrys poorest, it hovers around a meager 66 because of a raft of inequalities, such as diet, stress, smoking, pollution and health care.) For most people, health starts gradually diminishing in the last 15 years of life with the onset of chronic conditions, including arthritis, neurodegeneration and diabetes. If we could eliminate such diseases of aging, experts say, the US could save an estimated $7.1 trillion in health-care costs over the next 50 years. (Quite where all these sprightly centenarians might live on this already densely populated planet remains to be seen.)

Jim MellonEric Verdin

One of Mellons bets is on a class of drugs called senolytics, which destroy senescent cells: the so-called zombie cells that, for complex reasons, stop dividing as we age. Senescent cells harm the body by secreting compounds that cause inflammation in surrounding tissues. Many age-related conditionsarthritis, diabetes, Alzheimers, cancerhave an inflammatory component, and studies suggest that a buildup of senescent cells is a large part of the problem.

A number of biotech start-ups are devel- oping drugs that target cell senescence, but the furthest along is Unity Biotechnology, a company in South San Francisco that has three drugs in clinical trials to address aging conditions, starting with osteoar- thritis of the knee. Unity raised more than $200 million from such big names as Thiel and Bezos, who chipped in through their investment firms, before going public in 2018. Since then, Mellon has also bought a small stake.

The holy grail of senolytics will be the development of a preventive therapy to wipe out senescent cells in the body before they cause conditions of aging, theoretically extending life span. In June, a team from Sloan Kettering published new breakthrough research showing that CAR T cellstypically used for precision cancer therapycan also be used to target and kill senescent cells. Prescription senolytics for anti-aging therapy are still years away, but unsurprisingly, theres an audience of longevity enthusiasts who want to access such anti-aging miracles yesterdayand no shortage of FDA-unapproved ways to chase after them. For instance, after a few studies examined the senolytic effects of a chemotherapy drug called dasatinib, the website FightAging.org published a step-by-step guide to senolytic self-experimentation using chemotherapeutics.

It doesnt take a Ph.D. in biochemistry to guess that taking off-label chemo drugs might come with harmful side effects, but that hasnt stopped a zealous group of body-hackers from trying it themselves and chronicling their efforts online. The internet is littered with novice longevity adviceand sketchy anti-aging companies eager to separate the hopeful and desperate from their money, like the company that charges $8,000 for transfusions of plasma from the blood of teenagers and early-twentysomethings (yes, just like Gavin Belson on HBOs Silicon Valley). Many of these are at best ineffective and at worst deadly, since the same cellular systems that fuel growth in young people might cause cancer when tipped into overdrive. Imagine the tragic irony of paying tens of thousands for a therapy that promises to help you live longer but actually causes the cancer that kills you.

Adobe

Beyond the obvious red flags of repurposed chemo drugs and the bloodletting of teens, it can be difficult for a layperson to separate the world-changing longevity breakthroughs from the terrible ideas. Enter one of the worlds leading experts on longevity to help make sense of things.

Eric Verdin, 63, is president and CEO of the Buck Institute, a globally renowned center for aging research just outside San Francisco in Marin County. Verdin is bullish on the promise of living healthfully to at least 100. Today. But 180? Dont count on it. My prediction, based on everything we know today, is that getting to 120 is about the best we can do for the foreseeable future. Ill bet my house were not going to see anyone live to 180 for another 200 years, if ever, he says. But making everyone a healthy centenarian, this is something we can do today. And thats something to be excited about.

Verdins own lab at the Buck Institute studies the aging immune system and how its affected by lifestyle factors, such as nutrition and exercise. Informed by this research, Verdin follows a time-restricted diet in which he eats all of his meals in an eight-to-nine-hour window (similar to the Buchinger Wilhelmi process) and gets plenty of exercise mountain biking in Marins steep hills. The good news is that over 90 percent of what causes diseases of aging is environmental, and that means its within your control, he says.

But he emphasizes that responsible management of your health comes with limits, like avoiding experimental therapies. A group of people have decided to try some expensive and dangerous interventions, but there is zero evidence that any of these are going to help them live longer, he says. The problem, according to Verdin, is that the results of aging interventions in mouse trials can look very promising but rarely translate to success in humans. Theres a huge delta between the health of a stressed lab mouse and an optimally healthy mouse, Verdin says. So when you treat lab mice with longevity therapeutics, you see an outsized result that doesnt at all guarantee the same result in humans.

On the other hand, Verdin tells Robb Report, there are definitely new protocols worth getting excited about. Take, for instance, rapalogs, a class of drugs that interact with a protein called mTOR, which serves as a linchpin for multiple critical biological processes, including cell growth and metabolism. Rapalog drugs tamp down mTOR, possibly preventing age-related diseases such as diabetes, stroke and some cancers. The drug rapamycin, the most heavily studied formula, was approved in the US in 1999 to help prevent organ-transplant rejection. Last year the medical journal Aging published a rapturous opinion piece by oncologist Mikhail Blagosklonny in which he made the case that rapamycinin small or intermittent dosesis effective as a preventive treatment to ward off diseases of aging, and that, in the elderly, not taking rapamycin may be even more dangerous than smoking.

Eric VerdinJim Hughes Photography

Later this year, a biotech firm called resTORbio, which was spun out of the Swiss-based Big Pharma company Novartis in 2017, is expected to seek FDA approval for its rapalog RTB101, which clinical trials have shown to slow age-related decline of the immune system and improve immune response in elderly people by more than 20 percent, a key factor in protecting vulnerable aging populations from disease. (It is currently in trials on elderly patients with Covid-19.) This is the furthest-along program of anything in the aging field, Joan Mannick, cofounder and chief medical officer of resTORbio, told MIT Technology Review last year. If health authorities approve this drug well have a product for people to prevent age-related diseases. Not just in our lifetime, but in, you know, a few years.

One of the many effects of rapamycin is that it mimics the mechanisms of calorie restriction. As Verdins lab and others have shown, fasting provides a number of anti-aging benefits, including insulin regulation, reduced inflammation and, to put it colloquially, clearing out the gunky by-products of metabolismpart of the reason Twitter CEO Jack Dorsey and other tech titans eat just a few meals per week. For lesser mortals, fasting is extremely hard to commit to and not much fun, hence the huge interest in calorie-restriction mimetics like rapamycin, which provide all the benefits without the downer not-eating part.

Of all the calorie-restriction mimetics, the one sparking the most excitement among longevity researchers is already on the market: metformin, a decades-old diabetes drug. Metformin became a part of the Silicon Valley health regimen several years ago after an epidemiological study showed that Type 2 diabetics who took the drug lived longer than non-diabetics who didnt. Just about everyone in the longevity industry takes metformin, Verdin tells me. He takes it himself, and nearly everybody I interviewed is taking or has taken it, too.

In April, Nir Barzilai, the renowned endocrinologist who spearheaded research on the anti-aging properties of metformin, announced in an opinion piece he co-authored in the journal Cell Metabolism that his lab is launching a large clinical trial to investigate the anti-aging effects of the drug on non-diabetic populations. Barzilais goal is to prove to the FDA that aging itselfrather than conditions associated with it, like Alzheimers and arthritiscan be targeted as a disease. If Barzilai is successful and the FDA approves aging as a treatment indication, the process of bringing longevity therapies to market would accelerate rapidly.

Just as the FDA was able to move faster to bring Covid-19 therapies to market this year, we will reach a tipping point when public opinion pushes the FDA to approve aging as an indication, and the longevity-research field will make leaps as a result, Mellon says. He has contributed funding to Barzilais metformin research, which he believes will be instrumental in proving that there are compounds that can extend human life across the board.

The fact of the matter is that the US has the best regulatory system for new drug development in the world, Mellon says. Were in the first era ever when humans can be bioengineered to live longer. And in 10 years, well have solutions that are even better than today. Just wait, its coming.

Liz Parrish

Jim Mellon

Diet:Vegetarian.Mindfulness practice:Nightly meditation.

Exercise regimen:30 minutes of cardio and 10 minutes of weights,five days a week.

Anti-aging Rx:Regenerative gene therapies. Im certain most peoplewill take them in the next couple decades.

180th-birthday wish:Solving another critical issue.

Sleep routine:7.5 hours plus a 30-minute nap; in bed by 9 p.m.

Vitamins/supplements/ prescription meds:Vitamins D and B12, metformin.

Exercise regimen:Walk or run minimum 10,000 steps a day;weights three times week.

Anti-aging Rx:Green tea.

100th-birthday wish:Another 25 years.

Dave Asprey

Jim Hughes Photography

180th-birthday wish:Either a cruise to Mars or a 1970 Mustang Fastback,which by then will be 210 years old!

Sleep Routine:Avoid: coffee after 2 p.m., heavy workouts after 6 p.m.,alcohol during the week and heavy eating in the evening.

Vitamins/supplements:Vitamin D, omega fatty acids, NMN, citrus bioflavonoidcomplex, fiber supplement, prebiotic supplement.

Diet:Fasting-mimicking diet once every four to six months;roughly 16:8 intermittent fasting at other times.

Mindfulness practice:Daily meditation.

Anti-aging Rx:I love cooking and eating, so I do not restrict foodon the weekend. Happiness with friends and family is thesurest path to longevity.

100th-birthday wish:A bike tour across the US, from coast to coast.

The rest is here:
Why Silicon Valley Execs Are Investing Billions to Stay Young - Robb Report

A Washburn woman with a reputation for kindness and hard work is celebrating a century alive, and letters of congratulations are coming from all over.

PRESQUE ISLE, Maine A Washburn woman with a reputation for kindness and hard work is celebrating a century alive, and letters of congratulations are coming from all over.

The Presque Isle Rehab and Nursing Center held a 100th birthday party for Dorothy Dot Sperrey on July 24. Wearing a tiara and a sash that read 100 and fabulous, she received well-wishes from dozens of residents as well as some high-ranking officials among her 75 birthday cards included one from Sen. Susan Collins. President Donald Trump also sent a letter of congratulations.

A litany of nursing home staff attended as family members watched from outside unable to enter because of restrictions due to the COVID-19 pandemic. It was a sign of the times for a woman who has lived a lifetime of history.

On July 25, 1920, Sperrey was born into a vastly different Aroostook County and United States. The president was Woodrow Wilson, alcohol was illegal nationwide and women were only given the right to vote 24 days after Sperreys birth.

Dorothy Sperrey, right, appears in a photo from around 1941. Sperrey was around 21 at the time. (Reproduction by David Marino Jr.)

She is one of very few Americans who can vividly recall scenes of the 1920s. Her earliest memory is watching her mother nurse her newly born sister, Naida, around 1922. She remembers when her family got their first car in 1928 for $800 (about $12,000 adjusted for inflation). It was great to have their only previous mode of transportation was by horse.

In her teens, Sperrey worked on the historic Benjamin C. Wilder House on Main Street in Washburn, now a museum. Sperrey would clean, do laundry, cook and watch children in the home, at the time owned by the Jardine Family. Her work at the house introduced her to her eventual husband, Atwood Sperrey.

Sperrey, whose maiden name is Valley, married Atwood on April 20, 1939. They would remain married for more than 73 years, raising six children before his death in 2012. It is likely one of the longest lasting marriages in The Countys recent history.

Announcement of a bridal shower held for Dorothy Valley (later Sperrey) from a Star-Herald article published on April 6, 1939. She would get married exactly two weeks later. (Digital Archives, Mark and Emily Turner Memorial Library)

The Sperreys were an agricultural family that raised potatoes, peas and oats. Dorothy took an active role on the family farm, waking up at the crack of dawn to cut seed in the spring and harvest in the fall while doing all the cooking and cleaning required around the house as she raised half a dozen children.

Sperrey loved to cook her homemade chocolate doughnuts were well-known amongst family members make crafts and crochet. Religion was also an important aspect of her and her familys life. A longtime member of the Washburn Pentecostal Church, she often hosted traveling missionaries from South Asia and Africa. Now unable to read the Bible, her daughter Connie reads passages to her every night.

Her generosity is well-known in the Washburn community. One day, a school bus broke down near her home during one of Aroostook Countys notorious winter storms. As Sperrey recalls, she let the dozens of children inside, keeping them warm and even baking Rice Krispie squares for all of them. Her kindness wasnt forgotten one of those students sent Sperrey a birthday card celebrating her achievement.

Sperreys daughter, Anita McLellan, said that her mother has no life-threatening health issues and takes very little medication. There are other examples of longevity in their family: a few of her mothers siblings had lived into their 90s, including Naida Valley Parks, 97, who lives in Caribou.

People aged 100 or older, known as centenarians, make up an exclusive and miniscule subsection of the American population in 2014, there were only about 72,197, according to federal data. Sperrey attributed her longevity to living a clean life inspired by her upbringing.

My mother and father never smoked or drank or anything like that, and they never said you should do this or that, Sperrey said. But, we just knew by their example what they stood for, and we stood for that.

Go here to see the original:
Washburn woman who was born before women had the right to vote turns 100 - The County

Buy Photo

The DTE Training and Development Center off Cherry Hill Road. (Photo: JOHN HEIDER | hometownlife.com)

In government, taxes make the world go round.

Last year, the City of Westland collected$93,879,944in taxes between the summer and winter collections. Over $7.5 million of that came from just 10 businesses. These businesses employ, house, power and receive business from residents of the city and its surrounding communities.

Taxes bring in money that help fundcities, schools, librariesand more. It's up to elected officials to decide how that money is spent.

"In Michigan, it's generally around 60 to 70 percent of their operating budget," said Tim Hodge, a professor of economics at Oakland University."Property taxes make up the lion's share."

In Westland, those big payers include DTE Energy, the Westland Mall, Consumers Energy and a number of apartment complexes.

Westland Shopping Center off Warren Road.(Photo: JOHN HEIDER | hometownlife.com)

A property's tax billis determined by its taxable value;which is determined by things likelongevity of the owner, inflationandmarket value;multiplied by the various millage rates landowners pay.

"Whatever the millage rates are for the city, the schools, the county, the community colleges, all of those are put on there and calculated based on the taxable value of the property," Steve Smith, Westland's finance director, said.

Because ownership longevity is a factor, two properties that serve the same function might have two very different tax bills.

"You can't compare a taxable value on a property from one to the other even if they're the exact same structure," Jennifer Stamper, Westland's city assessor, said."They may have been sold at different times, which is going to affect the taxable value, one may have added a small addition to it that changes the value."

Westland's Westwood Village appartments. (Photo: JOHN HEIDER | hometownlife.com)

Businesses can appeal their state equalized value with their state, which, if lowered, can lower their taxable value and therefore their tax bill. But according to Stamper, exemptions are few and far between.

According to the state department of treasury, none of Westland's top 10 taxpayers were approved for any of Michigan's major exemptions during either collection in 2019.

"There are certain exemptions under state law, but they are very few," Stamper said."We as a city cannot just decide that we're going to give an exemption on a certain property because we feel like we want to help them out."

Stamper and Smith said the city cannot decide how much a landowner pays in property taxes, no matter how much business certain properties may bring to the city.

"We can't arbitrarily decide what to charge them for taxes," Smith said."It's all based on formulas and laws."

Contact reporterShelby Tankersley at stankersle@hometownlife.com or 248-305-0448. Follow her on Twitter@shelby_tankk.

Read or Share this story: https://www.hometownlife.com/story/news/local/westland/2020/08/11/westlands-highest-property-tax-payers-contribute-thousands-city/4952357002/

Continue reading here:
Show me the money: Here's who pays the most property taxes in Westland - Hometown Life

As part of her 'Hessentour - Benefits of Digitalization', Hessian Minister for Digital Strategy and Development Professor Kristina Sinemus visited BRAIN AG in Zwingenberg. The Minister informed herself about the importance and application fields of digitalization in industrial biotechnology.

Scientists from BRAIN AG explained to the Minister the role of digitally-supported analysis of initially unmanageable amounts of data in the field of metagenome analysis - and the identification and characterization of enzymes that can later be used in industrial processes.

Identifying microorganisms and their biomolecules digitally

Scientists at BRAIN described the metagenome as the entire genetic information of all genomes, e.g. in a soil sample, and the microbial diversity it contains. According to the scientists, the acquisition of digital data on microbial diversity (metagenome sequencing), followed by the digital classification of the sequence data (metagenome annotation) and their digital evaluation (comparative analysis) is the only way to process such biodiversity. As an example, they cited the fact that digitalized metagenomics could be used to identify and characterize up to 1010 microorganisms from a single gram of a soil sample. These in turn would provide an enormous variety of new biomolecules, such as proteins and enzymes, for biotechnological application.

Optimization between laboratory bench and database

Once a biomolecule has been digitally identified, it is advisable to create a 'digital variant library' (with more than 105 biomolecules in some cases) and optimize it using bioinformatics. This so-called 'protein engineering' is then checked in analogue laboratory tests, making it possible to optimize an enzyme step by step and under predefined conditions for cyclical applications on an industrial scale.

According to the scientists who held the presentation, this digital optimization process would sometimes involve the use of structural models that predict a digital 3D model from the one-dimensional linear amino acid sequence of an enzyme. These 3D models allowed predictions to be made about 'set screws' with which an enzyme could be improved: for example, the enzyme's temperature or pH optimum could be adapted to industrial processes in this way.

The Minister, herself a qualified biologist, followed the explanations with great interest. In the ensuing dialogue, she wanted to know what benefits this digitalization application would have for people themselves. The scientists at BRAIN explained that the current digital possibilities - particularly in combination with the often cited artificial intelligence - might enable hitherto unknown processes, such as the correct folding of digitally identified enzymes, which could make such efficient predictions based on the wealth of metagenome data that it would be possible to save repeated cycles between laboratory and database. Apart from this practical benefit for the daily work of scientists, society as a whole also benefits from the new digital possibilities, because optimized enzymes can, for example, reduce the energy required in an industrial process or the amount of chemicals needed, thus leading to greater sustainability.

Picture: The Hessian Minister for Digital Strategy and Development Prof. Dr. Kristina Sinemus and Adriaan Moelker, CEO of BRAIN AG, in a laboratory of biotech company BRAIN. BRAIN AG

Disclaimer

BRAIN - Biotechnology Research And Information Network AG published this content on 11 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 August 2020 11:57:01 UTC

Read more:
BRAIN Biotechnology Research and Information Network : Hessian Minister for Digital Strategy and Development visits BRAIN AG - marketscreener.com

SAN DIEGO and PENNINGTON, N.J., Aug. 10, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer will present at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020.

The OncoSec presentation will begin at 12:30 PM ET and will available via webcast at https://wsw.com/webcast/btig/oncs/.

In addition, the Company will be available for virtual one-on-one meetings on August 10th and 11th. Interested parties should register for the conference via https://btig.meetmax.com/BTIGBiotech20.

About OncoSec Medical IncorporatedOncoSec Medical Incorporated is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead product candidate, TAVO, enables the intratumoral delivery of DNA-based interleukin-12 or IL-12, a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors. The company is currently evaluating TAVO in combination with the anti-PD-1 checkpoint inhibitor, KEYTRUDA (pembrolizumab), in two KEYNOTE clinical trials, including a pivotal trial in patients with anti-PD-1 checkpoint resistant metastatic melanoma and a phase 2 trial in metastatic triple negative breast cancer. OncoSec is also identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its novel Visceral Lesion Applicator designed to target deep internal lesions, such as liver, lung or pancreatic lesions. For more information, please visit http://www.oncosec.com.

TAVO is a trademark of OncoSec Medical Incorporated.

KEYTRUDAis a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Risk Factors and Forward-Looking StatementsThis release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company's current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company's control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will" and "would" and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified, and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission ("SEC"). In particular, you should be aware that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, the impact of COVID-19 on the supply of our candidates or the initiation or completion of clinical trials and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2019 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC's websitewww.sec.gov), as well as other factors described from time to time in the Company's filings with the SEC.

Story continues

Original post:
OncoSec to Present at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020 - Yahoo Finance

The Global Industrial Biotechnology Market Research Report methodically describes every component of the market and assists the reader in evaluating the current and future market trends and formulate business expansion strategies. The key growth trends and opportunities are offered through a comprehensive investigation and examination of the market. A detailed course of development is provided in the report, along with insights into businesses connected with it, which include firms, industries, organizations, vendors, and local manufacturers. Better products and services to gain global and regional market share form the competitive landscape of the industry.

The report is studied with reference to the current COVID-19 pandemic. The pandemic has impacted several segments of the market on both the global and regional levels. The market report comprises of extensive research done on the current and in the post-COVID-19 scenario for the market. The study covers the present and future impact of the COVID-19 crisis on the market.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1338

The report provides an in-depth analysis of the competitive landscape and covers profiles of key players, along with their product portfolios and business strategies.

Key players of the market mentioned in the report are:

BASF, Amyris, Borregaard, BioAmber, Codexis, Evolva, Fermentalg, Gevo, Global Bioenergies, Deinove, Metabolic Explorer, Novozymes, and Solazyme

The global Industrial Biotechnology market has been exponentially growing on a global scale. The upstream raw materials, increase in the population, expanding regions, demand and supply, and advancements in technologies have contributed to the increasing growth figures. Various analytical tools like SWOT analysis, Porters Five Forces analysis, and others are implemented in the study to provide a deeper analysis of the market and its competitive landscape. Furthermore, the report covers market history, changing scenarios, demand and supply, manufacturing, production and consumption ratio, and technological developments.

The report further studies the segmentation of the market based on product types offered in the market and their end-use/applications.

Type Outlook (Revenue, USD Million; 2016-2026)

Raw Material Outlook (Revenue, USD Million; 2016-2026)

Application Outlook (Revenue, USD Million; 2016-2026)

Request customization of the report @ https://www.reportsanddata.com/request-customization-form/1338

Regional bifurcation mentioned in the Industrial Biotechnology market report:

Focal Points of the Reports TOC:

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1338

Key objectives of the Industrial Biotechnology research report:

To get the Report Description and TOC, visit @ https://www.reportsanddata.com/report-detail/industrial-biotechnology-market

Thank you for reading our report. For more details on customization, please reach out to us. Our team will ensure the report is tailored as per your requirements.

David is an Experience Business writer who regularly contributes to the blog, He specializes in manufacturing news

Read the original:
Industrial Biotechnology Market Insights Business Opportunities, Current Trends And Restraints Forecast 2026 | Reports And Data - Levee Report

Ligand Pharmaceuticals Inc. (LGND) is around the top of the Biotechnology industry according to InvestorsObserver. LGND received an overall rating of 77, which means that it scores higher than 77 percent of all stocks. Ligand Pharmaceuticals Inc. also achieved a score of 90 in the Biotechnology industry, putting it above 90 percent of Biotechnology stocks. Biotechnology is ranked 16 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Ligand Pharmaceuticals Inc. (LGND) stock is lower by -3.25% while the S&P 500 is up 1.19% as of 1:47 PM on Wednesday, Aug 12. LGND is down -$3.64 from the previous closing price of $111.90 on volume of 172,921 shares. Over the past year the S&P 500 has risen 15.28% while LGND is up 15.11%. LGND lost -$1.38 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Ligand Pharmaceuticals Inc. click here.

Read the rest here:
Is Ligand Pharmaceuticals Inc. (LGND) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Avid Bioservices Inc (CDMO) is near the top in its industry group according to InvestorsObserver. CDMO gets an overall rating of 68. That means it scores higher than 68 percent of stocks. Avid Bioservices Inc gets a 80 rank in the Biotechnology industry. Biotechnology is number 16 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 68 would rank higher than 68 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Avid Bioservices Inc (CDMO) stock is trading at $8.05 as of 2:32 PM on Wednesday, Aug 12, a gain of $0.35, or 4.55% from the previous closing price of $7.70. The stock has traded between $7.72 and $8.37 so far today. Volume today is 390,347 compared to average volume of 464,260.

To screen for more stocks like CDMO click here.

See more here:
Is Avid Bioservices Inc (CDMO) a Winner in the Biotechnology Industry? - InvestorsObserver

TEL AVIV, Israel, Aug. 12, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the second quarter ended June 30, 2020. The Company's six-month progress includes the development of several strategic initiatives, including growth-oriented opportunities in pain management and COVID-19 related therapeutics.

"Despite the COVID-19 pandemic business disruptions and the near-term delays to completing and commencing our clinical programs in Israel and the U.S., respectively, we acted swiftly over the past few months to leverage our sought-after technology to create several long-term business initiatives to enhance our value," commented Dr. Shai Yarkoni, Chief Executive Officer. "In addition to pursuing a potential merger with a global leader in the high growth medical-grade cannabis market, which is being delayed due to COVID-19, we have either initiated or are contemplating other business development activities that will greatly benefit from our innovation, technology and know-how. I believe each of these opportunities represents meaningful catalysts for Cellect in multi-billion-dollar markets, subject to resolution of the COVID-19 pandemic and return to normal course of business."

Notwithstanding the continued delays due to COVID-19, the Company remains focused on the following operational and clinical objectives:

The Company's cash and cash equivalents totaled $7 million as of June 30, 2020, which includes the approximately $1.5 million (gross before expenses)resulting from several investors exercising certain warrants that were issued in February 2019.

SecondQuarter 2020 Financial Results:

*For the convenience of the reader, the amounts above have been translated from NIS into U.S. dollars, at the representative rate of exchange on June 30, 2020 (U.S. $1 = NIS 3.466).

About Cellect Biotechnology Ltd.

Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

The Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company's current clinical trial is aimed at bone marrow transplantations in cancer treatment.

Forward Looking Statements

This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect's expectations regarding timing of the commencement of its planned U.S. clinical trial and its plan to reduce operating costs. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community; difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; the Company's ability to retain or attract key employees whose knowledge is essential to the development of its products; and the Company's ability to pursue any strategic transaction or that any transaction, if pursued, will be completed. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal year ended December 31, 2019 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, http://www.sec.gov, and in the Company's periodic filings with the SEC.

Cellect Biotechnology Ltd.

Consolidated Statement of Operation

Convenience

translation

Six months

ended

Six months ended

Three months ended

June 30,

June 30,

June 30,

2020

2020

2019

2020

2019

Unaudited

Unaudited

U.S. dollars

NIS

(In thousands, except share and per

share data)

Research and development expenses

837

2,901

7,086

1,364

3,564

General and administrative expenses

1,356

4,703

5,064

2,116

2,709

Operating loss

2,193

7,604

12,150

3,480

6,273

Financial expenses (income) due to warrants exercisable into shares

1,098

3,807

(7,111)

4,697

(5,919)

Other financial expenses (income), net

(15)

(55)

880

627

462

Total comprehensive loss

3,276

11,356

5,919

8,804

816

Loss per share:

Basic and diluted loss per share

0.010

0.034

0.029

0.024

0.004

Weighted average number of shares outstanding used to compute basic and diluted loss per share

338,182,275

338,182,275

200,942,871

365,428,101

224,087,799

Cellect Biotechnology Ltd.

Consolidated Balance Sheet Data

Convenience

translation

June 30,

June 30,

December 31,

2020

2020

2019

Unaudited

Unaudited

Audited

U.S. dollars

NIS

(In thousands, except share and per

share data)

CURRENT ASSETS:

Link:
Cellect Biotechnology Reports Second Quarter Financial and Operating Results; First Half 2020 Strategic Developments Create Long-Term Revenue...

The 47 rating InvestorsObserver gives to Beam Therapeutics Inc (BEAM) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 41 percent of stocks in the Biotechnology industry, BEAMs 47 overall rating means the stock scores better than 47 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 47 would rank higher than 47 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Beam Therapeutics Inc (BEAM) stock is down -6.18% while the S&P 500 is up 1.19% as of 2:33 PM on Wednesday, Aug 12. BEAM has fallen -$1.46 from the previous closing price of $23.62 on volume of 519,613 shares. Over the past year the S&P 500 is up 0.83% while BEAM is up 18.19%. BEAM lost -$2.68 per share the over the last 12 months.

To screen for more stocks like BEAM click here.

View original post here:
Where Does Beam Therapeutics Inc (BEAM) Stock Fall in the Biotechnology Field? - InvestorsObserver

In the latest report, Report Ocean has provided unique insights about the Biotechnology Market. This report provides in detail analysis of market with revenue growth and upcoming trends. Biotechnology Market research report derived key statistics, based on the market status of the manufacturers and is a valuable source of guidance and direction for companies and individuals interested in Biotechnology Market.

This research report offers in-depth study about Market Size and Share, Product and Services, Company Profile, Regional Forecast, Consumer Preference, Market Competition, and Industry Chain Structure.

This research report represents the statistical data in the form of TABLES, CHARTS, and infographics to assess the market, its growth and development, and market trends of the Biotechnology Market during the forecasted period.

COVID 19 Impact on Biotechnology Market

The Coronavirus Pandemic (COVID-19) has affected every aspect of life worldwide. Under COVID-19 Outbreak, how the Biotechnology Market Industry will develop is also analyzed in detail in Chapter 1.7 of the report.

In Chapter 2.4, we analyzed industry trends in the context of COVID-19.

In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets.

In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries.

In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=mai31385

competitive landscape:

Key players in the global Biotechnology market covered in Chapter 4:DanaherF. Hoffmann-La RocheThermo Fisher ScientificAgilent TechnologiesMerckQiagenIlluminaPerkinElmerAmgenBio-Rad LaboratoriesBioGen Medical InstrumentsAbbott Laboratories

This report also outlines the Major companies or players involved in the Biotechnology Market industry, along with product specifications, revenue generated, pricing strategies, contact information, information related to raw materials, equipment and demands. With the help of tables and figures, valuable insights on production, value, price, and gross margin of each player are offered.

Market Segmentation:

The segmentation study is considered as the key section to decide the target market with keen study of segments or smaller sections such as geographical regions, application and product type to optimize advertising technique and marketing strategies at regional as well as global level of the Biotechnology Market.

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2020-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:

North America (Covered in Chapter 6 and 13)

United States

Canada

Mexico

Europe (Covered in Chapter 7 and 13)

Germany

UK

France

Italy

Spain

Russia

Others

Asia-Pacific (Covered in Chapter 8 and 13)

China

Japan

South Korea

Australia

India

Southeast Asia

Others

Middle East and Africa (Covered in Chapter 9 and 13)

Saudi Arabia

UAE

Egypt

Nigeria

South Africa

Others

South America (Covered in Chapter 10 and 13)

Brazil

Argentina

Columbia

Chile

Others

Some of the Major Highlights of TOC covers:

Report Overview

Study Scope

Key Market Segments

Regulatory Scenario by Region/Country

Market Investment Scenario Strategic

Global Market Growth Trends

Industry Trends

SWOT Analysis

Porters Five Forces Analysis

Potential Market and Growth Potential Analysis

Industry News and Policies by Regions

Industry News

Industry Policies

Industry Trends Under COVID-19

Value Chain Biotechnology Market

Value Chain Status

Biotechnology Market Manufacturing Cost Structure Analysis

Production Process Analysis

Manufacturing Cost Structure of Biotechnology Market

Labor Cost of Biotechnology Market

Labor Cost of Biotechnology Market Under COVID-19

Sales and Marketing Model Analysis

Downstream Major Customer Analysis (by Region)

Value Chain Status Under COVID-19

Biotechnology Market Production, Revenue (Value), Price Trend by Type

Production and Market Share by Type

Revenue and Market Share by Type

Price by Type

Biotechnology Market Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Country

Production, Revenue, Price and Gross Margin

Industrial Chain, Sourcing Strategy and Downstream Buyers

Biotechnology Market Industrial Chain Analysis

Raw Materials Sources of Biotechnology Market major Players in 2019

Downstream Buyers

Biotechnology Market Forecast

Biotechnology Market Sales, Revenue and Growth Rate

Biotechnology Market Production, Consumption, Export and Import Forecast by Region

Biotechnology Market Production, Revenue and Price Forecast by Type

Biotechnology Market Consumption Forecast by Application

Biotechnology Market Forecast Under COVID-19

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2026

Inquire or Share Your Questions If Any before Purchasing This Report:https://www.reportocean.com/industry-verticals/sample-request?report_id=mai31385

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Link:
COVID-19 Impact on Biotechnology Market 2020 future development, manufacturers, trends, share, size and forecast edited by leading research firm -...

The 67 rating InvestorsObserver gives to Capricor Therapeutics Inc (CAPR) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, CAPRs 67 overall rating means the stock scores better than 67 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Capricor Therapeutics Inc (CAPR) stock has fallen -12.65% while the S&P 500 is higher by 1.27% as of 11:28 AM on Wednesday, Aug 12. CAPR is lower by -$0.85 from the previous closing price of $6.72 on volume of 1,273,064 shares. Over the past year the S&P 500 is up 15.37% while CAPR is higher by 96.98%. CAPR lost -$1.66 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Go here to read the rest:
Is Capricor Therapeutics Inc (CAPR) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

At the end of the latest market close, Unity Biotechnology Inc. (UBX) was valued at $11.98. In that particular session, Stock kicked-off at the price of $12.20 while reaching the peak value of $12.29 and lowest value recorded on the day was $11.31. The stock current value is $11.78.

Recently in News on August 4, 2020, UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital. UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it has entered into a $80 million debt facility with Hercules Capital [NYSE: HTGC]. You can read further details here

Unity Biotechnology Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the companys stock is recorded $15.44 on 08/10/20, with the lowest value was $4.62 for the same time period, recorded on 03/13/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Unity Biotechnology Inc. shares are logging -23.70% during the 52-week period from high price, and 154.98% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $4.62 and $15.44.

The companys shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1416746 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Unity Biotechnology Inc. (UBX) recorded performance in the market was 63.38%, having the revenues showcasing 70.48% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 626.46M, as it employees total of 100 workers.

During the last month, 0 analysts gave the Unity Biotechnology Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 7.76, with a change in the price was noted +6.65. In a similar fashion, Unity Biotechnology Inc. posted a movement of +129.63% for the period of last 100 days, recording 418,635 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity The total Debt to Equity ratio for UBX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Unity Biotechnology Inc. in the period of last 50 days is set at 55.31%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 51.94%. In the last 20 days, the companys Stochastic %K was 63.33% and its Stochastic %D was recorded 74.31%.

If we look into the earlier routines of Unity Biotechnology Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 63.38%. Additionally, trading for the stock in the period of the last six months notably improved by 83.20%, alongside a boost of 76.35% for the period of the last 12 months. The shares increased approximately by 15.15% in the 7-day charts and went down by 59.40% in the period of the last 30 days. Common stock shares were driven by 70.48% during last recorded quarter.

Go here to read the rest:
Unity Biotechnology Inc. (UBX) market price of $11.78 offers the impression of an exciting value play - The InvestChronicle

Industry Overview of Agriculture Biotechnology Market Report 2020

Market Expertz has published yet another new report on the global Agriculture Biotechnology market. This report can help the user to better understand the opportunities and threats that are doled by the industry and its players. Additionally, this study is inclusive of the market scenario and factors like the players who influence and dominate the industry. The strategies of these players, the products they offer, their operating areas, and the opportunities are discussed in detail. The report serves the analysis of the global market share, segmentation, revenue growth estimation, and geographic regions of the market.

The report includes the latest coverage of the impact of COVID-19 on the Agriculture Biotechnology industry. The incidence has affected nearly every aspect of the business domain. This study evaluates the current scenario and predicts future outcomes of the pandemic on the global economy.

To request for a free sample of the insightful Agriculture Biotechnology market report click [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/88805

This study analyses the growth of Agriculture Biotechnology based on the present, past and futuristic data and will render entire information about the Agriculture Biotechnology industry to the market-leading industry players that will guide the direction of the Agriculture Biotechnology market through the forecast period. All of these players are analyzed in detail to get details concerning their recent announcements and partnerships, product/services, investment strategies, and so on.

Competitive Landscape:

Agriculture Biotechnology market report highlights key players included in the market in order to render a comprehensive view of the competing players existing in the market. Company details, strategies, aptitude, history, cost analysis, and prevalent strategies

Leading Agriculture Biotechnology manufacturers/companies operating at both regional and global levels:

ADAMA Agricultural SolutionsVilmorinBayerBiocentury TransgeneCertisDow AgroSciencesEurofinsEvogeneGlobal Bio-chem TechnologySyngentaKWS SaatMarina BiotechMonsantoOthers

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

The Agriculture Biotechnology market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, markets and materials, CAPEX cycle, and the dynamic structure of the Agriculture Biotechnology market.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.marketexpertz.com/discount-enquiry-form/88805

Industry outlook:

Agriculture Biotechnology product types, applications, geographies, and end-user industries are the key market segments that are comprised in this study. The report speculates the prospective growth of the different market segments by studying the current market standing, performance, demand, production, sales, and growth prospects existing in the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Agriculture Biotechnology sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In market segmentation by types of Agriculture Biotechnology, the report covers-

BiochipsDeoxy ribonucleic acid (DNS) sequencingGenome editing toolsRibonucleic acid interference (RNAI)Synthetic biologyOthers

In market segmentation by applications of the Agriculture Biotechnology, the report covers the following uses-

Transgenic crops marketSynthetic biology-enabled products marketOthers

This Agriculture Biotechnology report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

Click here to inquire about customization and available discounts on the [emailprotected] https://www.marketexpertz.com/customization-form/88805

Highlights of the Agriculture Biotechnology market study:

Speculations for sales:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Agriculture Biotechnology market. Additionally, it includes a share of every segment of the Agriculture Biotechnology market, giving methodical information about types and applications of the market.

Key point summary of the Agriculture Biotechnology market report:

In the end, the Agriculture Biotechnology market is analyzed for revenue, sales, price, and gross margin.

Report customization:

Market Expertz also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Read the full Research Report along with a table of contents, facts and figures, charts, graphs, etc. @ https://www.marketexpertz.com/industry-overview/agriculture-biotechnology-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

About Us:Planning to invest in market intelligence products or offerings on the web? Then marketexpertz has just the thing for you reports from over 500 prominent publishers and updates on our collection daily to empower companies and individuals catch-up with the vital insights on industries operating across different geography, trends, share, size and growth rate. Theres more to what we offer to our customers. With marketexpertz you have the choice to tap into the specialized services without any additional charges.

Contact Us:John WatsonHead of Business Development40 Wall St. 28th floor New York CityNY 10005 United StatesDirect Line: +1-800-819-3052Visit our News Site: http://newssucceed.com

David is an Experience Business writer who regularly contributes to the blog, He specializes in manufacturing news

Original post:
How Agriculture Biotechnology Market Will Dominate In Coming Years? Key Players: ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene -...

The 29 rating InvestorsObserver gives to Tauriga Sciences Inc (TAUG) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 13 percent of stocks in the Biotechnology industry, TAUGs 29 overall rating means the stock scores better than 29 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 29 means the stock is more attractive than 29 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Tauriga Sciences Inc (TAUG) stock is unmoved 5.4% while the S&P 500 has risen 0.52% as of 2:42 PM on Tuesday, Aug 11. TAUG is flat $0.00 from the previous closing price of $0.03 on volume of 935,630 shares. Over the past year the S&P 500 has risen 17.16% while TAUG is flat 0.00%. TAUG lost -$0.04 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Tauriga Sciences Inc click here.

View post:
Is Tauriga Sciences Inc (TAUG) The Right Choice in Biotechnology? - InvestorsObserver

It is our aim to provide our readers with report for Pharmaceuticals and Biotechnology R&D Market, which examines the industry during the period 2020 2026. One goal is to present deeper insight into this line of business in this document. The first part of the report focuses on providing the industry definition for the product or service under focus in the Pharmaceuticals and Biotechnology R&D Market report. Next, the document will study the factors responsible for hindering and enhancing growth in the industry. After covering various areas of interest in the industry, the report aims to provide how the Pharmaceuticals and Biotechnology R&D Market will grow during the forecast period.

The major vendors covered:

ROCHE, JOHNSON & JOHNSON, MERCK, NOVARTIS, PFIZER, SANOFI, BAYER, BRISTOL-MYERS SQUIBB, ASTRAZENECA, GLAXOSMITHKLINE, ABBVIE, ELI LILLY, BOEHRINGER SOHN, AMGEN, GILEAD SCIENCES, TAKEDA PHARMACEUTICAL, NOVO NORDISK, BIOGEN, ABBOTT, ASTELLAS PHARMA, TEVA PHARMACEUTICAL INDUSTRIES and more

The final report will add the analysis of the Impact of Covid-19 on Pharmaceuticals and Biotechnology R&D Market.

Request a sample copy @ https://www.reportsandmarkets.com/sample-request/global-pharmaceuticals-and-biotechnology-r-d-market-size-status-and-forecast-2020-2026?utm_source=bulletinline&utm_medium=38

The Pharmaceuticals and Biotechnology R&D Market report between the years 2020 2026 will highlight the current value of the industry. At the same time, there is also an estimate of how much this line of business will be worth at the end of the forecast period. As it is our goal to maintain high levels of accuracy at all times, we will take a look at the CAGR of the Pharmaceuticals and Biotechnology R&D Market. We make sure that all the information available in this report has excellent levels of readability. One way we achieve this target is by Pharmaceuticals and Biotechnology R&D Market segmentation. Going through the report for 2020 2026 will bring our readers up-to-date regarding this industry.

While examining the information from this document, one thing becomes clear, the elements which contribute to increase in demand for the product or service. At the same time, there will be a focus on what drives the popularity of these types of products or services. This report is for those who want to learn about Pharmaceuticals and Biotechnology R&D Market, along with its forecast for 2020 2026. Information regarding market revenue, competitive partners, and key players will also be available.

Segmentation

As discussed earlier, there is segmentation in the Pharmaceuticals and Biotechnology R&D Market report, to improve the accuracy and make it easier to collect data. The categories which are the dividing factors in the industry are distribution channels, application, and product or service type. With this level of segmentation, it becomes easier to analyze and understand the Pharmaceuticals and Biotechnology R&D Market. At the same time, there is emphasis on which type of consumers become the customers in this industry. When it comes to distribution channels, the Pharmaceuticals and Biotechnology R&D Market report looks at the different techniques of circulation of the product or service.

Regional Overview

In this part of the Pharmaceuticals and Biotechnology R&D Market report, we will be taking a look at the geographical areas and the role they play in contributing to the growth of this line of business. The areas of interest in this document are as follows Middle East and Africa, South and North America, Europe, and Asia Pacific. From the Pharmaceuticals and Biotechnology R&D Market report, it becomes clear which region is the largest contributor.

Latest Industry News

From this Pharmaceuticals and Biotechnology R&D Market report, the reader will also get to learn about the latest developments in the industry. The reason is that these products or services have the potential to disrupt this line of business. If there is information about company acquisitions or mergers, this information will also be available in this portion of the Pharmaceuticals and Biotechnology R&D Market report.

If you have any special requirements about this Pharmaceuticals and Biotechnology R&D Market report, please let us know and we can provide custom report.

Inquire more about this report @ https://www.reportsandmarkets.com/enquiry/global-pharmaceuticals-and-biotechnology-r-d-market-size-status-and-forecast-2020-2026?utm_source=bulletinline&utm_medium=38

About Us

ReportsAndMarkets.com allocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serve our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Originally posted here:
Pharmaceuticals and Biotechnology R&D Market Growth, Statistics, By Application, Production, Revenue & Forecast To 2026 - Bulletin Line

Vir Biotechnology, Inc. (NASDAQ:VIR) went down by -1.02% from its latest closing price when compared to the 1-year high value of $75.00 and move down -42.42%, while VIR stocks collected 4.07% of gains with the last five trading sessions. Press Release reported 8 hours ago that Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results

Vir Biotechnology, Inc. (NASDAQ:VIR) 2 of the analysts out of 5 who provided ratings for Vir Biotechnology, Inc. stocks as a buy while 0 as overweight, 1 rated it as hold and 1 as sell. The average price we get from analysts is $32.50 which is -$17.99 below current price. VIR currently has a short float of 3.28% and public float of 106.55M with average trading volume of 1.47M shares.

VIR stocks went up by 4.07% for the week, with the monthly jump of 4.86% and a quarterly performance of 74.03%. The simple moving average for the period of the last 20 days is 5.77% for VIR stocks with the simple moving average of 82.96% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with JP Morgan repeating the rating for VIR shares by setting it to Underweight. The predicted price for VIR socks in the upcoming period according to JP Morgan is $26 based on the research report published on March 19, 2020.

Goldman, on the other hand, stated in their research note that they expect to see VIR stock at the price of $26. The rating they have provided for VIR stocks is Neutral according to the report published on March 13, 2020.

Robert W. Baird gave Underperform rating to VIR stocks, setting the target price at $17 in the report published on February 27, 2020.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, Vir Biotechnology, Inc. was unable to take a rebound, for now settling with -29.79% of loss for the given period.

The stock volatility was left at 6.16%, however, within the period of a single month, the volatility rate increased by 6.47%, while the shares surge at the distance of +6.21% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +48.97% upper at the present time.

In the course of the last 5 trading sessions, VIR went up by +4.07%, which changed the moving average for the period of 200 days to the total of +268.25% of gains for the stock in comparison to the 20-day moving average settled at $49.94. In addition, Vir Biotechnology, Inc. saw 318.77% in overturn over the period of a single year with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at Vir Biotechnology, Inc. (VIR), starting from Pang Phillip, who sold 12,500 shares at the price of $50.90 back on Aug 05. After this action, Rushing now owns 15,777 shares of Vir Biotechnology, Inc., valued at $636,222 with the latest closing price.

Pang Phillip, the Chief Medical Officer of Vir Biotechnology, Inc., sold 12,500 shares at the value of $50.90 during a trade that took place back on Aug 05, which means that Pang Phillip is holding 15,777 shares at the value of $636,222 based on the most recent closing price.

The current profitability levels are settled at -2144.35 for the present operating margin. The net margin for Vir Biotechnology, Inc. stands at -2158.98. Total capital return value is set at -62.52, while invested capital returns managed to touch -62.97.

Based on Vir Biotechnology, Inc. (VIR), the companys capital structure generated 0.27 points for debt to equity in total, while total debt to capital is set at the value of 0.27.

Read the original here:
Is a Correction Looming Ahead? Vir Biotechnology, Inc. (VIR) - The News Heater

The PDS Biotechnology Corporation (PDSB) shares are trading at lower $3.00 and the avg recommendation for the stock is Moderate Buy. while the current analyst price target stands at $6.48.

To add more color to this target, the companys high over the last year is $6.51 and the low is $0.62. Over the last 52 weeks, PDSB is down -53.92% while the S&P 500 is down -0.83%. The catalyst for this interesting swing was the companys recent earnings report.

A Notable Earnings Report

PDSB Return on Equity (ROE) is -105.10%, and its Return on Assets is -85.20%. All told, it is clear that, PDSB needs to be on your watchlist.

Find out when PDSB reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. PDSB has a short ratio of 0.37 and outstanding shares of 10.32M.

Company Outlook

PDSB has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 1.39 million and more growth is possible in the weeks ahead. Traders will also note the companys earnings per share came in at -3.02. PDS Biotechnology Corporation PDSB also noted assets of $23.93 million at the end of the last quarter. Investors should also keep an eye on sector updates as PDSB has historically followed its peers on positive news.

All told, PDS Biotechnology Corporation PDSB has strung together solid data and demonstrated underlying fundamentals. At its current valuation, PDSB represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

PDS Biotechnology Corporation PDSB is now commanding a market cap of 45.33M and a float of 9.77M. PDSB is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of PDSB stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in PDSB, either long or short, and we have not been compensated for this article.

Post Views: 60

Read this article:
The Rejuvenation of PDS Biotechnology Corporation (NASDAQ:PDSB) - The Oracle Dispatch

Next-Generation Biomanufacturing Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis. It also provides market information in terms of development and its capacities.

Next-Generation Biomanufacturing Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample?reportId=280469

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in This Report:

Applikon Biotechnology BV, bbi-biotech GmbH, Danaher Corporation, Eppendorf AG, Esco Group of Companies, GEA Group Aktiengesellschaft, Meissner Filtration Products, Inc., Merck KGaA, PBS Biotech, Inc., Pierre Gurin, Sartorius AG, Shanghai Bailun Biotechnology Co. Ltd., Solaris Biotechnology Srl., Thermo Fisher Scientific Inc., ZETA GmbH

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Next-Generation Biomanufacturing market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Next-Generation Biomanufacturing markets trajectory between forecast periods.

Buy Exclusive Report with Attractive Discount @:

https://www.a2zmarketresearch.com/discount?reportId=280469

Reasons for buying this report:

Table of Contents

Global Next-Generation Biomanufacturing Market Research Report 2020 2026

Chapter 1 Next-Generation Biomanufacturing Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Next-Generation Biomanufacturing Market Forecast

If You Have Any Query, Ask Our Experts:

https://www.a2zmarketresearch.com/enquiry?reportId=280469

If you have any special requirements, please let us know and we will offer you the report as you want.

Link:
Next-Generation Biomanufacturing Market will touch a new level in upcoming year with Top Key Players like Applikon Biotechnology BV, bbi-biotech GmbH,...